FDA Approves JUVÉDERM VOLBELLA XC for Undereye Hollows
Allergan Aesthetics, an AbbVie company, announces the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21.
Allergan Aesthetics, an AbbVie company, announces the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21.
The neurotoxin is characterized by a rapid onset of action as early as eight hours after administration and a shorter duration of effect of two to three weeks.